tradingkey.logo
搜尋

First Tracks Biotherapeutics Ord Shs

TRAX
添加自選
47.100USD
-1.600-3.29%
收盤 11-13 16:00(美東)
1.98B總市值
0.00本益比TTM

First Tracks Biotherapeutics Ord Shs

47.100
-1.600-3.29%

關於 First Tracks Biotherapeutics Ord Shs 公司

First Tracks Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. The Company's clinical-stage pipeline includes Rosnilimab, a selective pathogenic T cell depleter, for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a blood dendritic cell antigen 2 (BDCA2) modulator. Rosnilimab is an IgG1 antibody that directly targets pathogenic T cells, such as activated Tph/Tfh and T effector cells, in the periphery or inflamed tissue. Rosnilimab is designed to selectively deplete pathogenic T cells while sparing non-pathogenic T cells, including naive T cells, to preserve overall immune function and restore immune homeostasis. Its molecules have applicability across a range of autoimmune and inflammatory diseases, including gastroenterology, rheumatology and other areas.

First Tracks Biotherapeutics Ord Shs 簡介

公司代碼- -
公司名稱- -
上市日期- -
CEO- -
員工數量- -
證券類型- -
年結日- -
公司地址- -
城市- -
上市交易所- -
國家- -
郵編- -
電話- -
網址- -
公司代碼- -
上市日期- -
CEO- -

First Tracks Biotherapeutics Ord Shs公司高管

名稱
名稱/職務
職務
持股
持股變動
Mr. Daniel R. Faga
Mr. Daniel R. Faga
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.02M
--
Mr. Daniel R. Faga
Mr. Daniel R. Faga
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.02M
--
Mr. Daniel R. Faga
Mr. Daniel R. Faga
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.02M
--
Mr. John P. Schmid
Mr. John P. Schmid
Independent Director
Independent Director
37.65K
-292.53%
Mr. John P. Schmid
Mr. John P. Schmid
Independent Director
Independent Director
37.65K
-292.53%
Mr. John P. Schmid
Mr. John P. Schmid
Independent Director
Independent Director
37.65K
-292.53%
Dr. Rita Jain, M.D.
Dr. Rita Jain, M.D.
Independent Director
Independent Director
19.19K
-319.15%
Dr. Rita Jain, M.D.
Dr. Rita Jain, M.D.
Independent Director
Independent Director
19.19K
-319.15%
Dr. Rita Jain, M.D.
Dr. Rita Jain, M.D.
Independent Director
Independent Director
19.19K
-319.15%
Mr. John A. Orwin
Mr. John A. Orwin
Independent Chairman of the Board
Independent Chairman of the Board
17.89K
-310.79%
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Daniel R. Faga
Mr. Daniel R. Faga
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.02M
--
Mr. Daniel R. Faga
Mr. Daniel R. Faga
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.02M
--
Mr. Daniel R. Faga
Mr. Daniel R. Faga
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.02M
--
Mr. John P. Schmid
Mr. John P. Schmid
Independent Director
Independent Director
37.65K
-292.53%
Mr. John P. Schmid
Mr. John P. Schmid
Independent Director
Independent Director
37.65K
-292.53%
Mr. John P. Schmid
Mr. John P. Schmid
Independent Director
Independent Director
37.65K
-292.53%

常見問題

First Tracks Biotherapeutics Ord Shs的前五大股東是誰?

First Tracks Biotherapeutics Ord Shs的前五大股東如下:Mr. Daniel R. Faga
tradingkey.logo
風險提示:我們的網站和行動應用程式僅提供關於某些投資產品的一般資訊。Finsights 不提供財務建議或對任何投資產品的推薦,且提供此類資訊不應被解釋為 Finsights 提供財務建議或推薦。
投資產品存在重大投資風險,包括可能損失投資的本金,且可能並不適合所有人。投資產品的過去表現並不代表其未來表現。
Finsights 可能允許第三方廣告商或關聯公司在我們的網站或行動應用程式的任何部分放置或投放廣告,並可能根據您與廣告的互動情況獲得報酬。
© 版權所有: FINSIGHTS MEDIA PTE. LTD. 版權所有